NCT00213902

Brief Summary

The objectives of this study are:

  1. 1.To evaluate the effect of clonidine, a sympathetic modulator, to reverse cardiac remodeling and to improve hemodynamics in diastolic heart failure (DHF).
  2. 2.To evaluate the effect of clonidine on neurohormones and quality of life in patients with DHF.
  3. 3.placebo (n=35) or to
  4. 4.clonidine (n=35) in a dose of 0.075 mg twice a day for the first 6 weeks followed by uptitration to 0.150 mg twice a day for 6 months.

Trial Health

10
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P25-P50 for all trials

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2004

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

September 13, 2005

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 21, 2005

Completed
Last Updated

November 29, 2007

Status Verified

November 1, 2007

First QC Date

September 13, 2005

Last Update Submit

November 28, 2007

Conditions

Ventricular Dysfunction

Keywords

Heart failureDiastolicfunctionClonidineLeft ventricular diastolic dysfunction with preserved ejection fraction

Eligibility Criteria

Age60 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age: 60 and greater
  • Gender: Both
  • Patients with heart failure New York Heart Association (NYHA) II and ejection fraction over 45%

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Ventricular DysfunctionHeart FailureHeart Murmurs

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Pascal Bousquet, MD

    Hopitaux Universitaires de Strasbourg

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 13, 2005

First Posted

September 21, 2005

Study Start

April 1, 2004

Last Updated

November 29, 2007

Record last verified: 2007-11